French agency head quits over delayed withdrawal of slimming pill
This article was originally published in Scrip
Jean Marimbert, the head of the French drug and device regulatory agency (AFSSAPS), is resigning from his post in face of growing criticism from the general public that the agency took too long to withdraw Servier's slimming drug Mediator (Benfluorex Hydrochloride) from the market. AFSSAPS, a key player in the European pharmaceutical regulatory network, suspended the marketing of Mediator in 2009.
You may also be interested in...
The UK Medicines and Healthcare products Regulatory Agency is developing a series of guidance documents on general points to consider when planning a trial to generate real-world evidence. The first document in this series focuses on prospective randomized trials.
With still no guarantee of what kind of access the UK will have to the EU’s all-important Article 57 database after the Brexit transition period ends, drug companies will have to provide key information about their pharmacovigilance systems directly to the UK medicines regulator.
More than a year after UK health technology assessment body NICE started offering scientific advice on designing patient preference studies, only two companies have sought guidance. NICE has also contributed to related projects that it hopes will increase the relevance of such studies in the context of an HTA appraisal.